Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (ARWR) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · ARWR · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
67
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Arrowhead Pharmaceuticals, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
ARWR insider buying and selling by quarter
ARWR insider selling · ARWR insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · ARWR ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
ARWR executive sell shares · ARWR board member insider trading · ARWR insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| May 12, 2026 | Lu Hongbo Director | Sale | 2,970 | $228K | Form 4 |
| Apr 22, 2026 | Apel Daniel Joseph CFO | Sale | 3,208 | $225K | Form 4 |
| Apr 22, 2026 | Apel Daniel Joseph CFO | Sale | 1,157 | $82K | Form 4 |
| Apr 22, 2026 | Apel Daniel Joseph CFO | Sale | 8,730 | $628K | Form 4 |
| Apr 23, 2026 | Hamilton James C Chief Medical Officer | Sale | 10,000 | $750K | Form 4 |
| Mar 5, 2026 | Hamilton James C Chief Medical Officer | Sale | 10,000 | $642K | Form 4 |
| Jan 6, 2026 | Hamilton James C Chief Medical Officer | Award | 75,000 | — | Form 4 |
| Jan 6, 2026 | Apel Daniel Joseph CFO | Award | 75,000 | — | Form 4 |
| Jan 6, 2026 | O'Brien Patrick COO | Award | 75,000 | — | Form 4 |
| Jan 6, 2026 | O'Brien Patrick COO | Gift | 540 | — | Form 4 |
| Jan 6, 2026 | O'Brien Patrick COO | Gift | 540 | — | Form 4 |
| Jan 6, 2026 | O'Brien Patrick COO | Gift | 540 | — | Form 4 |
| Jan 6, 2026 | O'Brien Patrick COO | Gift | 440 | — | Form 4 |
| Jan 6, 2026 | O'Brien Patrick COO | Gift | 440 | — | Form 4 |
| Dec 31, 2025 | O'Brien Patrick COO | Gift | 560 | — | Form 4 |
| Dec 31, 2025 | O'Brien Patrick COO | Gift | 560 | — | Form 4 |
| Dec 31, 2025 | O'Brien Patrick COO | Gift | 560 | — | Form 4 |
| Dec 31, 2025 | O'Brien Patrick COO | Gift | 560 | — | Form 4 |
| Dec 31, 2025 | O'Brien Patrick COO | Gift | 560 | — | Form 4 |
| Jan 5, 2026 | O'Brien Patrick COO | Sale | 4,368 | $267K | Form 4 |
| Jan 5, 2026 | O'Brien Patrick COO | Sale | 6,164 | $384K | Form 4 |
| Jan 5, 2026 | O'Brien Patrick COO | Sale | 13,451 | $847K | Form 4 |
| Jan 5, 2026 | O'Brien Patrick COO | Sale | 11,842 | $756K | Form 4 |
| Jan 5, 2026 | O'Brien Patrick COO | Sale | 2,700 | $174K | Form 4 |
| Jan 5, 2026 | O'Brien Patrick COO | Sale | 900 | $59K | Form 4 |
Hamilton James C
Chief Medical Officer
Date
Apr 23
Shares
10,000
Price
$75.00
Value
$750K
Hamilton James C
Chief Medical Officer
Date
Mar 5
Shares
10,000
Price
$64.19
Value
$642K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About ARWR insider trading
ARWR insider trades
Arrowhead Pharmaceuticals, Inc. (ARWR) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Anzalone Christopher Richard (CEO · Director), O'Brien Patrick (COO), Hamilton James C (Chief Medical Officer). Over the past 12 months, 5 insiders have filed transactions with the SEC. ARWR insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Arrowhead Pharmaceuticals, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
ARWR insider trading · 5 questionsThe insiders of Arrowhead Pharmaceuticals, Inc. (ARWR) include executives and directors such as Anzalone Christopher Richard (CEO · Director), O'Brien Patrick (COO), Hamilton James C (Chief Medical Officer), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026